Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis (HPDMT)
Recruitment status was: Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
|
Opiate Addiction |
Device: Combined hemoperfusion-hemodialysis Drug: Methadone |
Phase 3 |
First People's Hospital of Foshan has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Advances in Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis: A Comparison Study With Conventional Methadone Treatment (HPDMT) |
- The Short Opiate Withdrawal Scale(SOWS-Gossop) [ Time Frame: 15 days ]
- Blood levels of morphine and β-endorphin, and the urine level of morphine. [ Time Frame: 15 days ]
| Estimated Enrollment: | 60 |
| Study Start Date: | November 2009 |
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Combined hemoperfusion-hemodialysis
On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
|
Device: Combined hemoperfusion-hemodialysis
Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
|
|
Active Comparator: Methadone, conventional treatment for opiate detoxification
On admission thirty patients receive the 10-day methadone treatment regimen.
|
Drug: Methadone
On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
|
Detailed Description:
Drug abuse remains a major society problem in our community and is also a major health problem in our modern society. Thus, education to prevent the young generation to avoid drug abuse and detoxification to help those to quite from the drug abuse are two major key steps in the controlling drug abuse program.
Currently, medications for opiate detoxification, such as methadone, are commonly used worldwide. However, methadone is also an addictive medication. When it is stopped suddenly, patients usually produce unpleasant withdrawal symptoms. Meanwhile, methadone is also potentially to be abused too. Thus, it is urgently needed to seek an alternative safer, effective, drug-free method for opiate detoxification. Based on our clinical observation, the timely clearance of toxicities from the body or blood is a safe and effective detoxification method. Thus, we hypothesized that the use of combined hemoperfusion-hemodialysis may be an alternative drug-free, effective, and safe treatment for opiate detoxification. This will be tested in patients who have severe drug abuse and are under custodial conditions by a daily combined hemoperfusion-hemodialysis for 3 days. The efficacy and safety of the hemoperfusion-hemodialysis will be compared to a 10 day standard methadone detoxification treatment.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Be fulfilled DSM-IV criteria(American Psychiatric Association) for opiate dependence.
- A history of current dependence on heroin, which was supported by laboratory results from urine drug screening, using both chromatographic and radioimmunoassay methods.
- Opioid dependent patients who inject heroin from 0.5g to 1.0g daily by veins for at least 1 year.
- Haven't received methadone treatment for at least 2 months before entry to this study.
- Be able to understand and have signed the informed consent.
Exclusion Criteria:
- Take heroin for the first time.
- Positive for HIV.
- The function of cruor or hemorrhage is badly damaged.
- The number of platelets is lower than 70×10*9.
- Co-dependent on substances other than opiates (including alcohol, benzodiazepines, cocaine, or amphetamines).
- Methadone dose requirement is over 70 mg/day as determined by the 3-day dose assessment period.
- Have serious physical illness or major psychiatric illness.
- Pregnant woman.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01021566
| China, Guangdong | |
| the First People's Hospital of Foshan | |
| Foshan, Guangdong, China, 528000 | |
More Information
| Responsible Party: | the First People's Hospital of Foshan |
| ClinicalTrials.gov Identifier: | NCT01021566 History of Changes |
| Other Study ID Numbers: |
075783161516 |
| Study First Received: | November 27, 2009 |
| Last Updated: | November 27, 2009 |
Keywords provided by First People's Hospital of Foshan:
|
Opiate addiction Withdrawal symptoms hemoperfusion hemodialysis methadone |
Additional relevant MeSH terms:
|
Behavior, Addictive Opioid-Related Disorders Compulsive Behavior Impulsive Behavior Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Methadone Analgesics, Opioid |
Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Antitussive Agents Respiratory System Agents |
ClinicalTrials.gov processed this record on May 25, 2017